Christopher K Rayner1,2, Linda E Watson3, Liza K Phillips3,4, Kylie Lange3, Michelle J Bound3, Jacqueline Grivell3, Tongzhi Wu3,4, Karen L Jones3,4, Michael Horowitz3,4, Ele Ferrannini5, Domenico Tricò6, Silvia Frascerra7, Andrea Mari8, Andrea Natali7. 1. Centre of Research Excellence for Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia chris.rayner@adelaide.edu.au. 2. Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia. 3. Centre of Research Excellence for Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. 4. Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. 5. CNR Institute of Clinical Physiology, Pisa, Italy. 6. Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. 7. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 8. CNR Institute of Neuroscience, Padua, Italy.
Abstract
OBJECTIVE:Tachyphylaxis for slowing of gastric emptying is seen with continuous exposure to glucagon-like peptide 1 (GLP-1). We therefore aimed to establish whether prolonged use of a "short-acting" GLP-1 receptor agonist, lixisenatide, achieves sustained slowing of gastric emptying and reduction in postprandial glycemia. RESEARCH DESIGN AND METHODS: A total of 30 patients withmetformin-treated type 2 diabetes underwent assessment of gastric emptying (scintigraphy) and glucose metabolism (dual tracer technique) after a 75-g glucose drink, before and after 8 weeks' treatment with lixisenatide (20 μg subcutaneously daily) or placebo, in a double-blind randomized parallel design. RESULTS:Gastric retention of the glucose drink was markedly increased after lixisenatide versus placebo (ratio of adjusted geometric means for area under the curve [AUC] over 240 min of 2.19 [95% CI 1.82, 2.64], P < 0.001), associated with substantial reductions in the rate of systemic appearance of oral glucose (P < 0.001) and incremental AUC for blood glucose (P < 0.001). Lixisenatide suppressed both glucagon (P = 0.003) and insulin (P = 0.032), but not endogenous glucose production, over 120 min after oral glucose intake. Postprandial glucose lowering over 240 min was strongly related to the magnitude of slowing of gastric emptying by lixisenatide (r = -0.74, P = 0.002) and to the baseline rate of emptying (r = 0.52, P = 0.048) but unrelated to β-cell function (assessed by β-cell glucose sensitivity). CONCLUSIONS: Eight weeks' treatment with lixisenatide is associated with sustained slowing of gastric emptying and marked reductions in postprandial glycemia and appearance of ingested glucose. Short-acting GLP-1 receptor agonists therefore potentially represent an effective long-term therapy for specifically targeting postprandial glucose excursions.
RCT Entities:
OBJECTIVE: Tachyphylaxis for slowing of gastric emptying is seen with continuous exposure to glucagon-like peptide 1 (GLP-1). We therefore aimed to establish whether prolonged use of a "short-acting" GLP-1 receptor agonist, lixisenatide, achieves sustained slowing of gastric emptying and reduction in postprandial glycemia. RESEARCH DESIGN AND METHODS: A total of 30 patients with metformin-treated type 2 diabetes underwent assessment of gastric emptying (scintigraphy) and glucose metabolism (dual tracer technique) after a 75-g glucose drink, before and after 8 weeks' treatment with lixisenatide (20 μg subcutaneously daily) or placebo, in a double-blind randomized parallel design. RESULTS: Gastric retention of the glucose drink was markedly increased after lixisenatide versus placebo (ratio of adjusted geometric means for area under the curve [AUC] over 240 min of 2.19 [95% CI 1.82, 2.64], P < 0.001), associated with substantial reductions in the rate of systemic appearance of oral glucose (P < 0.001) and incremental AUC for blood glucose (P < 0.001). Lixisenatide suppressed both glucagon (P = 0.003) and insulin (P = 0.032), but not endogenous glucose production, over 120 min after oral glucose intake. Postprandial glucose lowering over 240 min was strongly related to the magnitude of slowing of gastric emptying by lixisenatide (r = -0.74, P = 0.002) and to the baseline rate of emptying (r = 0.52, P = 0.048) but unrelated to β-cell function (assessed by β-cell glucose sensitivity). CONCLUSIONS: Eight weeks' treatment with lixisenatide is associated with sustained slowing of gastric emptying and marked reductions in postprandial glycemia and appearance of ingested glucose. Short-acting GLP-1 receptor agonists therefore potentially represent an effective long-term therapy for specifically targeting postprandial glucose excursions.
Authors: Ryan J Jalleh; Karen L Jones; Christopher K Rayner; Chinmay S Marathe; Tongzhi Wu; Michael Horowitz Journal: Diabetologia Date: 2022-10-04 Impact factor: 10.460
Authors: Kieran Smith; Guy S Taylor; Lise H Brunsgaard; Mark Walker; Kelly A Bowden Davies; Emma J Stevenson; Daniel J West Journal: BMJ Open Diabetes Res Care Date: 2022-05
Authors: Carlos Bendicho-Lavilla; Iria Seoane-Viaño; Francisco J Otero-Espinar; Asteria Luzardo-Álvarez Journal: Acta Pharm Sin B Date: 2021-08-10 Impact factor: 11.413
Authors: Chinmay S Marathe; Hung Pham; Tongzhi Wu; Laurence G Trahair; Rachael S Rigda; Madeline D M Buttfield; Seva Hatzinikolas; Kylie Lange; Christopher K Rayner; Andrea Mari; Michael Horowitz; Karen L Jones Journal: Diabetes Ther Date: 2022-04-22 Impact factor: 3.595
Authors: Ryan J Jalleh; Tongzhi Wu; Karen L Jones; Christopher K Rayner; Michael Horowitz; Chinmay S Marathe Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Julie E Stevens; Ryan J Jalleh; Laurence G Trahair; Chinmay S Marathe; Michael Horowitz; Karen L Jones Journal: Br J Clin Pharmacol Date: 2022-03-21 Impact factor: 3.716
Authors: Ele Ferrannini; Elisabeth Niemoeller; Terry Dex; Soraly Servera; Andrea Mari Journal: Diabetes Obes Metab Date: 2022-03-28 Impact factor: 6.408